XSHG
603108
Market cap872mUSD
Oct 09, Last price
9.97CNY
1D
3.21%
1Q
6.18%
Jan 2017
-41.28%
IPO
99.80%
Name
Shanghai Runda Medical Technology Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shanghai Runda Medical Technology Co., Ltd. delivers a comprehensive array of integrated medical laboratory solutions throughout China. The company's extensive offerings cover vital operational aspects for laboratories, including the provision of essential platforms, expert design and refurbishment services for facilities, the establishment of standardization protocols, and the implementation of advanced information management systems. Furthermore, Shanghai Runda supports healthcare professionals by providing medical solutions for critical diagnostic fields such as biochemistry, diabetes, Point-of-Care Testing (POCT), immunoassay analysis, and molecular biology. Alongside these, they also furnish professional technical assistance and efficient logistical services. Established in 1999, the firm is headquartered in Shanghai, China.
Key people
Shanglin Liao
Chief Financial Officer · since 2020
Zhenning Hu
Deputy General Manager, Director · since 2023
Mo Chen
Director · since 2023
Hui Liu
Vice Chairman of the Board, General Manager · since 2023
Xiaoyan Lu
Deputy General Manager, Staff Elected Director · since 2026
Shenjie Yao
Director · since 2023
Chengxu Zhang
Chairman of the Board, Secretary of the Board · since 2023
Bin Zhao
Director · since 2026
Hwang Tong Chan
Independent Director · since 2023
Independent Director · since 2026
Jingjing Wang
Independent Director · since 2023
Mingwei Zhu
Independent Director · since 2026
Headquarters & legal address
上海市金山区卫昌路1018号1号楼201室
金山区, SH 100000
CN
金山区, SH 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||